Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Inflammatory bowel disease.

Noel B Martins1, Mark A Peppercorn

  • 1From Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA. nmartins@bidmc.harvard.edu

The American Journal of Managed Care
|September 9, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Using Adalimumab to Treat Autoimmune Enteropathy.

ACG case reports journal·2020
Same author

Insights into the treatment of inflammatory bowel disease in pregnancy.

Therapeutic advances in gastroenterology·2019
Same author

Octreotide as an adjunct in the management of arterial gastrointestinal bleeding: Should it be considered in refractory cases of obscure origin?

International journal of critical illness and injury science·2017
Same author

Immunosuppressive therapies for inflammatory bowel disease.

World journal of gastroenterology·2014
Same author

Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease.

Clinical and experimental gastroenterology·2011
Same author

Abdominal phlegmons in Crohn's disease: outcomes following antitumor necrosis factor therapy.

Inflammatory bowel diseases·2011
Same journal

Prescription drug prior authorization: costs to pharmacies and physicians.

The American journal of managed care·2026
Same journal

Combined pharmacotherapy and psychotherapy impact on opioid use disorder treatment.

The American journal of managed care·2026
Same journal

The societal costs of food insecurity: implications for managed care strategies.

The American journal of managed care·2026
Same journal

Availability of hospital financial assistance documents in non-English languages.

The American journal of managed care·2026
Same journal

Real-world weight loss with injectable semaglutide vs dulaglutide for diabetes.

The American journal of managed care·2026
Same journal

Social needs screening and supplemental benefits in Medicare Advantage.

The American journal of managed care·2026
See all related articles

Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, presents complex gastrointestinal and extraintestinal challenges. Reviewing IBD pathogenesis, manifestations, and treatments reveals potential long-term cost savings with newer therapies.

Area of Science:

  • Gastroenterology
  • Immunology
  • Internal Medicine

Background:

  • Inflammatory bowel disease (IBD) comprises Crohn's disease (CD) and ulcerative colitis (UC), affecting the intestine and extraintestinal sites.
  • Ongoing debate exists on whether CD and UC are distinct or part of a disease continuum.
  • IBD significantly impacts the healthcare system and economy due to its chronic nature.

Purpose of the Study:

  • To review the pathogenic mechanisms of IBD.
  • To outline the clinical manifestations of IBD.
  • To discuss current and emerging treatment options for IBD.

Main Methods:

  • Literature review of pathogenic mechanisms in IBD.
  • Analysis of clinical presentations across IBD subtypes.

Related Experiment Videos

  • Evaluation of treatment strategies and their economic implications.

    • Main Results:

    • Detailed review of IBD pathogenesis, including immunological and genetic factors.
    • Comprehensive overview of diverse clinical symptoms and extraintestinal manifestations.
    • Exploration of therapeutic interventions, from conventional to novel agents.

    Conclusions:

    • Understanding IBD pathogenesis and clinical diversity is crucial for effective management.
    • Newer, albeit more expensive, treatments may offer economic benefits through reduced healthcare utilization.
    • Further research into IBD continuum and cost-effective therapies is warranted.